Priovant's brepocitinib hits skin remission targets in Phase 3 DM trial
Priovant Therapeutics has announced the publication in JAMA Dermatology of skin-specific secondary endpoint results from the Phase 3 VALOR trial, adding granular cutaneous data to primary efficacy findings already reported in the New England Journal of Medicine. The new analysis focuses on disease activity, itch, and skin-related quality of life in adults with dermatomyositis (DM), a rare autoimmune condition that affects both skin and muscle.
Brepocitinib is an oral, once-daily inhibitor of TYK2 and JAK1, a dual-kinase profile that Priovant positions as selectively suppressing key cytokines implicated in autoimmunity, including type I and type II interferons, IL-6, IL-12, and IL-23. The 30 mg dose was evaluated against placebo in a 241-subject global study across 90 sites, with patients randomised 1:1:1 to brepocitinib 30 mg, brepocitinib 15 mg, or placebo.
Skin endpoint results
The numbers reported in JAMA Dermatology are notable across several dimensions. Among patients with at least moderate itch at baseline, 54% on brepocitinib 30 mg achieved a clinically meaningful itch reduction by Week 4, compared with fewer than 10% on placebo. By Week 52, that gap narrowed but remained substantial: 74% versus 33%. In patients with moderate-to-severe skin disease at baseline, 46% on the active arm achieved Clear or Almost Clear skin on the Investigator's Global Assessment, against 22% on placebo. Functional skin remission, defined as a Cutaneous Dermatomyositis Activity and Severity Index score of five or below, was reached by 44% of brepocitinib-treated patients versus 21% on placebo.
Steroid-tapering outcomes also favoured the active arm. Among patients on oral corticosteroids at baseline, 61.7% on brepocitinib 30 mg tapered to 2.5 mg/day prednisone-equivalent or below by Week 52, compared with 34.4% on placebo, and 41.7% discontinued corticosteroids entirely versus 23.4% in the placebo group. Reducing cumulative steroid burden is a meaningful clinical goal in DM given the well-documented toxicity of long-term systemic corticosteroid use.
Victoria P. Werth, Professor of Dermatology and Medicine at the Perelman School of Medicine at the University of Pennsylvania and a lead VALOR investigator, described the cutaneous findings as "a monumental finding for patients with dermatomyositis," noting that skin disease in DM carries a quality-of-life burden that "exceeds most other inflammatory skin diseases" and has historically been difficult to control with conventional therapies.
Competitive and regulatory context
Dermatomyositis is classified as an orphan disease and currently lacks any approved therapy specifically licensed for the indication; treatment relies largely off-label on corticosteroids, antimalarials, and immunosuppressants. Brepocitinib's Phase 3 VALOR data place it in a small group of agents generating late-stage controlled evidence in this space. The broader JAK inhibitor class has faced intensifying regulatory scrutiny from the FDA, EMA, and MHRA over cardiovascular, thromboembolic, and malignancy risks since the publication of the ORAL Surveillance data in 2022, and any regulatory submission for brepocitinib will need to address the class-wide black-box warning context. The company notes that in VALOR, new or recurrent malignancy, cardiovascular events, and thromboembolic events occurred more frequently in the placebo arm than in the brepocitinib 30 mg arm, though serious infections were higher on the active drug.
Beyond DM, Priovant is running Phase 3 programmes for non-infectious uveitis and cutaneous sarcoidosis, and a Phase 2b/3 study in lichen planopilaris, suggesting an autoimmune platform strategy built around the TYK2/JAK1 axis. Priovant is a subsidiary of Roivant Sciences, which is listed on Nasdaq. No regulatory submission timeline was disclosed in the current announcement.